- Home
- PHVS vs ATAI Comparison
PHVS vs ATAI Comparison
Compare PHVS & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHVS
- ATAI
- Stock Information
- Founded
- PHVS 2015
- ATAI 2018
- Country
- PHVS Switzerland
- ATAI Netherlands
- Employees
- PHVS N/A
- ATAI N/A
- Industry
- PHVS Biotechnology: Pharmaceutical Preparations
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- PHVS Health Care
- ATAI Health Care
- Exchange
- PHVS Nasdaq
- ATAI Nasdaq
- Market Cap
- PHVS 1.6B
- ATAI 1.6B
- IPO Year
- PHVS 2021
- ATAI 2021
- Fundamental
- Price
- PHVS $24.95
- ATAI $3.77
- Analyst Decision
- PHVS Buy
- ATAI Strong Buy
- Analyst Count
- PHVS 7
- ATAI 5
- Target Price
- PHVS $37.00
- ATAI $14.00
- AVG Volume (30 Days)
- PHVS 282.9K
- ATAI 5.1M
- Earning Date
- PHVS 11-12-2025
- ATAI 11-12-2025
- Dividend Yield
- PHVS N/A
- ATAI N/A
- EPS Growth
- PHVS N/A
- ATAI N/A
- EPS
- PHVS N/A
- ATAI N/A
- Revenue
- PHVS N/A
- ATAI $3,018,000.00
- Revenue This Year
- PHVS N/A
- ATAI $736.04
- Revenue Next Year
- PHVS N/A
- ATAI N/A
- P/E Ratio
- PHVS N/A
- ATAI N/A
- Revenue Growth
- PHVS N/A
- ATAI 811.78
- 52 Week Low
- PHVS $11.51
- ATAI $1.15
- 52 Week High
- PHVS $26.33
- ATAI $6.75
- Technical
- Relative Strength Index (RSI)
- PHVS 57.14
- ATAI 31.35
- Support Level
- PHVS $23.76
- ATAI $3.63
- Resistance Level
- PHVS $26.20
- ATAI $3.89
- Average True Range (ATR)
- PHVS 1.77
- ATAI 0.27
- MACD
- PHVS 0.19
- ATAI -0.06
- Stochastic Oscillator
- PHVS 75.19
- ATAI 16.75
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.
About ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.